A Phase 3 interventional study of Probiotic and Placebo in Chronic Periodontitis, sponsored by Next Gen Pharma India Pvt. Ltd.. Completed at 1 site in India. Open to participants aged 35 Years to 49 Years. Per ClinicalTrials.gov, last updated 2017-01-10.
Sponsored by Next Gen Pharma India Pvt. Ltd. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 53 studies in Chronic Periodontitis with a site in India — 2 open to participants now, 3 under way, none of them phase 3. Chronic Periodontitis · India.
Among the 53 studies in Chronic Periodontitis with a site in India, this one is the 34th largest by enrollment of the 46 interventional ones that give a count, is one of 12 that started in 2015, is one of 8 in phase 3, and was the 16th registered.
377 studies on the registry are indexed under Chronic Periodontitis; 21 are open to participants now.
Browse Chronic Periodontitis studies →2 of the 53 studies in Chronic Periodontitis with a site in India are open now. Recruiting first, the newest first:
Postgraduate Institute of Dental Sciences Rohtak · Sites in India
Ages 30–50
Postgraduate Institute of Dental Sciences Rohtak · Sites in India
Ages 30–50 · Healthy volunteers
A study can be open while its sites in India have not opened yet or have stopped. Only those recruiting at a site in India →
Of the 13 Chronic Periodontitis studies recruiting now, 7 (54%) set no upper age limit and 5 (38%) stop at 75 or younger; none take children under 18; 4 take healthy volunteers.
This study: 35 Years to 49 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
53 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 17 · Phase 3 17 · Phase 4 6
First in 2011; this study’s year is marked. 12 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 31 is below the median of 46 across 307 interventional studies indexed under Chronic Periodontitis.
Median enrollment 53 across the 46 interventional studies, 90 across the 7 observational. Of the 43 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 53 have an industry lead sponsor. The 10 most frequent:
Next Gen Pharma India Pvt. Ltd. is the lead sponsor of 4 studies on the registry; none are open to participants now.
Next Gen Pharma India Pvt. Ltd. has 2 studies filed under Chronic Periodontitis — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 53 studies in Chronic Periodontitis with a site in India, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Periodontitis is an infectious inflammatory disease. Bacteria modulate the inflammatory response and alter the diversity of periodontal disease. In recent years, various host-response modulation therapies have been developed to block the pathways responsible for periodontal tissue breakdown.
There have been significant changes with respect to the effectiveness of, and attitudes towards conventional antimicrobial therapy to combat disease. With the threat of widespread antibiotic resistance rendering many antibiotics useless against important diseases, there is an increased necessity not only to minimise antibiotic use and develop novel non-antibiotic-based treatments, but also to raise the profile of disease prevention. One approach that has gained interest over recent years is the use of probiotic bacteria for oral applications. The rationale for their use in oral health care stems from the increase in evidence that supports their claims for benefit for a range of diseases. Lactobacilli play an important role in the maintenance of health by stimulating the natural immunity as well as by contributing to the balance of the microflora, by interacting with the other members of the flora. The application of health promoting bacteria for therapeutic purposes, is one of the strongest emerging fields. Time has come to shift the paradigm of the treatment from specific bacteria elimination to alteration of the bacterial ecology by using probiotics.
So the purpose of this study is to discover a more promising approach for the treatment of chronic periodontitis .
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Placebo Lozenges (3 Lozenges per day; 1 lozenge in morning and 2 lozenges in the night). Each placebo lozenge contains all excipients except the active constituent (Lactobacillus brevis CD2)
Drug: Placebo
L. brevis CD2 Lozenges (3 Lozenges per day; 1 lozenge in morning and 2 lozenges in the night). Each probiotic lozenge contains not less than 1 billion CFU of L. brevis CD2
Drug: Probiotic
Each probiotic lozenge contains not less than 1 billion colony forming unit of Lactobacillus brevis CD2
Also known as: L. brevis CD2 Lozenges
Each placebo lozenge contains all excipients except the active constituent (Lactobacillus brevis CD2)
Improvement in Periodontal Clinical indices
Improvement in periodontal clinical indices, namely, Gingival Index (GI), Bleeding on probing (BOP), Probing Pocket Depth (PPD) and Clinical attachment Loss (CAL).
Time frame: 8 weeks
Change in bone pattern
Assessment of changes in bone patterns in bith group using digital radio-graphic technique
Time frame: 8 weeks
The record gives a start of Apr 2015, a primary completion of Sep 2016 and a completion of Dec 2016. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Probiotic
Next Gen Pharma India Pvt. Ltd.